Reversal of neuromuscular blockade (sugammadex vs neostigmine)
Avoid residual paralysis · Perioperative & Anaesthesia
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Residual neuromuscular blockade causes hypoxia, airway obstruction and aspiration. Reversal is guided by quantitative train-of-four (TOF) monitoring: sugammadex encapsulates aminosteroid relaxants (rocuronium/vecuronium) for rapid reliable reversal; neostigmine (with an antimuscarinic) reverses moderate block of any non-depolariser but cannot reverse deep block.
Red flags
- TOF ratio <0.9 at extubation (residual blockade)
- Weak cough, poor airway protection or desaturation after extubation
- Bradycardia/asystole from neostigmine without adequate antimuscarinic
- Recurarisation in recovery
- Anaphylaxis to sugammadex or rocuronium-sugammadex complex (rare)
Assessment
Differential diagnosis
- Residual neuromuscular blockade
- Central respiratory depression (opioids/anaesthetic)
- Pseudocholinesterase deficiency (prolonged suxamethonium block)
- Myasthenia gravis/neuromuscular disease
- Hypothermia, acidosis or electrolyte disturbance prolonging block
- Recurarisation
Investigations
- Quantitative train-of-four (TOF) monitoring - aim TOF ratio >=0.9 before extubation
- Assess clinical adequacy: sustained head lift, grip, tidal volume, ability to protect airway
- Review relaxant type, dose and timing
- Check temperature, pH and electrolytes (Mg, K) that potentiate block
- Consider plasma cholinesterase testing if prolonged suxamethonium block suspected
Management
- Use quantitative TOF monitoring on every patient receiving neuromuscular blockers - clinical signs alone are unreliable
- Do not extubate until TOF ratio >=0.9
- For rocuronium or vecuronium, choose sugammadex and dose by depth of block (shallower block needs less)
- Give sugammadex 2 mg/kg for reappearance of the second twitch (moderate block) and 4 mg/kg for deeper block (post-tetanic count 1-2)
- For immediate reversal of a rocuronium RSI intubating dose (e.g. can't intubate), give sugammadex 16 mg/kg
- For benzylisoquinolinium agents (atracurium/cisatracurium) or where sugammadex is unavailable, reverse moderate block with neostigmine plus an antimuscarinic
- Do NOT attempt neostigmine reversal of deep block (it has a ceiling effect and risks residual paralysis)
- Co-administer glycopyrronium (or atropine) with neostigmine to counter bradycardia and secretions
- Confirm adequate reversal clinically and by TOF before extubation
- Monitor for recurarisation in recovery, especially after reduced-dose or renally-excreted agents
Drugs & doses
Sugammadex 2 mg/kg IV for moderate rocuronium/vecuronium block (TOF T2 present)
Sugammadex 4 mg/kg IV for deep block (post-tetanic count 1-2, no TOF twitches)
Sugammadex 16 mg/kg IV for immediate reversal of a rocuronium RSI dose
Neostigmine 0.04-0.05 mg/kg IV (max ~5 mg) for moderate block of any non-depolariser
Glycopyrronium 10-15 microgram/kg IV (approx 200-400 microgram per 1 mg neostigmine) co-administered
Atropine 10-20 microgram/kg IV as alternative antimuscarinic with neostigmine
Disposition
Extubate in theatre only once TOF >=0.9; monitor in recovery for residual/recurarisation and escalate to critical care if reversal is inadequate.
Complications & pitfalls
- Residual paralysis causing hypoxia, airway obstruction and aspiration
- Neostigmine bradycardia, bronchospasm and secretions
- Sugammadex: hypersensitivity, and it binds hormonal contraceptives (counsel re additional contraception for 7 days)
- Recurarisation
- Prolonged recovery and critical care admission
Exam pearls
- Neostigmine CANNOT reverse deep block - it has a ceiling; use sugammadex for deep rocuronium/vecuronium block
- Quantitative TOF to >=0.9 is the standard - clinical tests miss significant residual block
- Sugammadex binds progesterone - advise 7 days of additional non-hormonal contraception after a single dose
- Sugammadex does NOT reverse benzylisoquinoliniums (atracurium/cisatracurium)
- After sugammadex, re-paralysis within 24h needs a benzylisoquinolinium or high-dose rocuronium - plan accordingly
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.